Brain cancer patients harmed under the care of University Hospitals Coventry and Warwickshire NHS Trust are demanding a public inquiry after a review found severe failures in its neuro-oncology service.
The Royal College of Physicians reviewed 20 cases linked to the care of retired clinical oncologist Prof Ian Brown, identified as Dr Y in the report. It found six patients suffered severe harm, five moderate harm and eight low harm. In one case, the reviewers could not decide between moderate and severe harm.
That is not a dispute about bedside manner. It is a documented account of treatment departing from national practice, with consequences measured in years.
The BBC reports that some patients were misdiagnosed, while others were told they would die if they stopped taking temozolomide, or TMZ, despite that not being true. The drug is usually given for six cycles over about six months after radiotherapy. The review found patients kept on repeated cycles for years. One patient received more than 100 cycles across 13 years and later developed leukaemia linked to excessive chemotherapy.
Becky Jones told the BBC she underwent 11 years of chemotherapy for a brain tumour she did not have. She is among more than 40 patients taking legal action against the trust. Mark Poulton said he spent a decade on TMZ before learning he had been wrongly diagnosed.
The trust has apologised. Chief executive Professor Andy Hardy and chair Sue Noyes said patients had been let down and the care fell far below expected standards. Brown did not take part in the review and refused to comment when approached by the BBC.
The part that should trouble the health authorities beyond Coventry is buried in the scale. The review examined 20 cases, but it also warned there may be many more affected patients. It identified 83 people who received extended TMZ treatment between 2017 and 2023 and said there is a “large cohort” of deceased patients who had the same non-standard regime and may also have come to harm.
The review stopped short of ordering a full retrospective examination of every dead patient’s care. Instead, it said any wider review should be discussed with the Department of Health and Social Care and NHS England because such an exercise would be significant and costly.
Patients are asking for something larger than an apology. They are asking who signed off on years of treatment outside standard practice, and why it took a doctor’s retirement for colleagues’ concerns to turn into an institutional reckoning.
Marcus Azzopardi
Elena Vella
Alex de Valletta